Understanding the investment opportunity
Heuristik is a software solution for patient identification and management that combines fingerprints with artificial intelligence.
Founded in 2019, Heuristik is a Spanish startup pioneering in the field of patient identification and management through biometric technology. Its innovative software, which combines fingerprints with artificial intelligence to identify fingerprints in adverse situations (dirty, wet, or blood-stained), has revolutionized the way medical centers identify and manage their patients, offering an efficient and secure solution to ensure accuracy in the healthcare process.
The idea behind Heuristik arose from a personal incident that deeply affected CEO and founder, Antxon Caballero. After his grandfather experienced a misidentification, receiving the wrong medication due to being confused with another patient, Antxon set out to find a solution to prevent other patients from facing similar situations.
Heuristik's technology not only offers secure and reliable identification but also simplifies administrative processes in healthcare environments, reducing errors and improving staff efficiency. Additionally, its focus on data security ensures compliance with privacy and data protection regulations (GDPR), providing peace of mind to both patients and healthcare providers.
Since its launch, Heuristik has been recognized for its impact on the healthcare industry, winning awards for its innovation and contribution to improving the quality of patient care. With a clear vision and unwavering commitment to excellence, Heuristik continues to lead the way toward a future where technology and healthcare come together to provide safer and more efficient care for all.
INVESTMENT STAGE
MARKET
- digital health
- artificial-intelligence
- biometrics
OFFICIAL WEBPAGE
Heuristik Team

Antxon Caballero
CEO

Ruben Lopez
CTO

Tatiana Yglesias
CSO

Jose Carlos Aradillas
Head of AI

Jonathan Sanz
Sr. Front end

Carlos Crisostomo
Sr. DevOps

Jorge Duran
Sr. Rust developer

Gerard Espuga
DPO

Thomas Carson
Director de Operaciones

Jose Ignacio Solaeche
BUSINESSANGEL

Xavier Castells
BUSINESSANGEL

Acex Healthcare
ACCELERATOR

EIT Health
ACCELERATOR

Health Venture Lab (GE Healthcare)
ACCELERATOR

Idea2 MIT
ACCELERATOR

MassChallenge
ACCELERATOR

Microsoft Founders Hub
ACCELERATOR

Nvidia Inception
ACCELERATOR

The Hill Oxford
ACCELERATOR
Reasons to invest View more data
VALIDATED TECHNOLOGY: Heuristik’s solution has been implemented and validated in 4 healthcare entities at the national level.
TRACTION: Heuristik has two signed contracts (Portugal and Italy) and 15 letters of interest from hospitals in 7 European countries (Spain, Portugal, Poland, Italy, Germany, Croatia, and Romania) plus Israel and the United States.
POTENTIAL MARKET: The healthcare biometrics market is valued at $81B, growing at a 19% CAGR.
PROPRIETARY TECHNOLOGY: Heuristik has developed 100% of its technology.
HARDWARE-AGNOSTIC: Heuristik’s software solution works with any fingerprint hardware on the market.
EXPERIENCED FOUNDING TEAM: Heuristik boasts a senior C-level team with members like Antxon, who had an exit with his previous company, Tatiana with over 20 years of experience working at Novartis Boston, and Ruben, a CTO with more than 15 years of experience managing tech teams. There are several notable team members: Jose Carlos, Ph.D. in Artificial Intelligence; Thomas, who was the fifth employee at a medical device startup in Switzerland and helped it grow to 70 employees; and Carlos Crisóstomo, with over 20 years of experience developing infrastructure as a DevOps engineer.
ADDRESSING A REAL PROBLEM: Heuristik was born 5 years ago when a nurse made an identification error involving the grandfather of Heuristik's CEO, Antxon Caballero. The WHO reports that the average rate of identification errors in hospitals is currently 10%, in Europe, there are more than 500M identification errors annually, with costs exceeding €200B.
INVESTORS, ACCELERATORS, AND MULTIPLE AWARDS BACK THE PROJECT:
Awards
- National award for the most impactful company by Fundación Repsol
- Vithas Acex Healthcare Award
- Madrid Impacta Award for the social company with the greatest growth potential and international projection
- Caelestinus Award for the company with the highest number of pilot projects
- Finalist of Santander X Global Healthcare Innovation Challenge (out of over 700 companies worldwide)
- Finalist of the European Health Tech Challengers
Accelerators
- MIT and MassChallenge (Boston)
- Nvidia and Microsoft (United States)
- GE Healthcare (Budapest)
- The Hill (Oxford)
- Acex Healthcare (Granada)
- EIT Health (Patient Innovation Bootcamp, Bridgehead, and EIC accelerator)
And in 2025, in collaboration with Hospital Da Luz in Portugal, the first results will be obtained for the publication of the paper, demonstrating that Heuristik’s solution is capable of identifying patients with 100% effectiveness and in a cost-efficient manner.
Who is the reference investor?

Xavier Castells
BUSINESSANGEL
About Xavier Castells
Xavier es un emprendedor en serie del mundo de las ciencias de la vida. En su experiencia como director y CFO de varias Startups ha colaborado activamente en la incorporación de dos empresas de ciencias de la vida a la bolsa (Inkemia y Vytrus Biotech) y está a punto de sacar la tercera. También ha colaborado activamente para Venture Funds del sector.- Investing in startups:> 10 years
- Invested Euros:1,5 M €
- Investments:11
- Exits:2
I have over 12 years of experience in the health sector, and I have seen that in recent years digital health has been experiencing significant growth. The digitization of hospitals and technologies that streamline processes are becoming increasingly important every day.
When I met Antxon, I was impressed by the passion he inspires and his ability to set aside his EGO and listen. I believe that the Heuristik solution is well-positioned for exponential growth once they conclude the phase they are currently immersed in.
Heuristik is a solution that not only helps reduce identification errors but also helps reduce hospital costs. For this reason, I believe they have a winning product.
It has also invested in...




Live
Chat


You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meOpportunity analysis Last update Jun 27, 2025 2:05:54 PM


You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meInvestor questions
The regulations governing Startupxplore's activity require that no investor is in possession of more information than the rest. Therefore, this section will provide answers to any questions asked by an investor about the opportunity.
If you have any doubts or questions about the startup, the process or any other aspect please write to us at coinversion@startupxplore.com


You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register meDocumentation


You need to be registered to view the content
This content is confidential and you must be registered with Startupxplore in order to access it.
Register me